Maves review
Maves offers compounded injection plans with separate introductory and ongoing prices. Its current clinical consent clarifies who provides care, while older payment and shipping documents need to be matched to the selected offer.
Maves review: introductory versus ongoing GLP-1 prices, Keeva clinical care, included injection kits, service states and shipping and cancellation qualifications.
Our verdict
Maves gives a prospective patient a useful distinction between the first purchase and the price advertised afterward. Compare the single-medication plan before considering its larger treatment bundles. The remaining work is to connect that offer with the agreement governing your actual care and payment. Keep the prescription, supplied quantity, renewal date and delivery terms together. A clear product card helps, but neither a promotional discount nor a cancel-anytime statement explains what happens to an order already being prepared. The clinical relationship also deserves its own check before a long-term budget is built around the offer.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
At a glance
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- States
- 36
- Prescription
- Required
- Updated
- October 2026
What it is
The current telehealth consent identifies Homera Health as the company operating the Maves platform and Keeva as the clinical organization. Administrative support and independent prescribing are separate responsibilities. Older general terms also mention Beluga and Bask-related services, so confirm the agreement presented with your enrollment rather than assuming every organization named across the site will handle your case. The product page identifies Michael Green as chief medical officer. That is a useful name to investigate, without promising that he will personally evaluate each patient or independently verifying professional credentials.
How it works
The newer consent allows real-time visits and later review of questionnaires, records or secure messages. A clinician can require additional testing or an in-person assessment when remote information is insufficient. Before starting, establish how to contact that clinician between orders and how treatment changes are documented. A portal message about symptoms should reach the clinical team, while a missing delivery needs the fulfillment contact. The consent explicitly leaves response times unguaranteed; access to messaging should not be confused with immediate assessment at every hour.
Pricing transparency
The dedicated GLP-1 page lists semaglutide at $189 initially, then $249 monthly, and tirzepatide at $249 initially, then $349 monthly. It includes compounded medication and an injection kit and advertises free expedited shipping. Treat those as the named program offers, not the price of every larger protocol. Keep the initial discount separate from ongoing spending. Confirm the selected prescription, dose, amount supplied and next charge before payment, especially if the enrollment summary differs from a general policy.
Branded vs compounded
The single-treatment page describes compounded semaglutide or tirzepatide given by weekly subcutaneous injection. Compounded drugs lack FDA approval and premarket FDA verification of safety, effectiveness or quality. The site also has treatment-specific safety information. Read the material for the exact prescribed preparation with the clinician rather than treating a general benefits description as individual advice. An advertised combination with another medicine is a different purchase and clinical decision; its claimed advantages should not become a reason to add treatment without discussing the evidence and alternatives.
Pros and watch-outs
What we like
- The product page separates the introductory charge from the ongoing rate.
- The current clinical consent distinguishes the platform from the treating medical group.
- A named service-state list makes location eligibility easier to check.
Watch-outs
- Older legal sections describe programs that should not automatically be applied to GLP-1 care.
- The general shipping policy and product-specific shipping promise need to be reconciled for the selected order.
- A broad support promise does not guarantee an immediate clinical response or a particular prescription.
Sources
- Current single-treatment prices, inclusions and administration route
- Clinical relationship, remote care and communication limits
- Practice description and named service states
- Broader protocols and coming-soon oral listing
- General platform and program-specific membership terms
- Processing, delivery charges, prescription returns and filling errors
- Platform information and communication privacy policy
- Provider-published treatment safety information
- FDA guidance on compounded-drug telehealth marketing
Best for
Someone comparing an ongoing injection program who will keep the selected offer, clinical agreement and renewal schedule together.
Who should look elsewhere
Someone choosing solely by the first-month discount or expecting every program and legal section to have identical payment conditions.
How Maves compares
A few alternatives worth a look, depending on what you’re optimizing for.
- SkinnyRx
A tirzepatide price you can check
See SkinnyRx → - Shed
Compounded pricing without a membership
See Shed → - RxSpan MD
Comparing plan terms upfront
See RxSpan MD →
More GLP-1 telehealth sellers reviews: Joi + BlokesJRNYSJumpstartMDJune HealthJustAnswer Weight LossJyra Health
Pricing & provider data · Last updated October 2026
How we assessed this. This review reflects GLP Loss’s own read of Maves’s publicly-stated model — pricing transparency, clinical oversight, medication clarity, and access — against our editorial methodology. We publish no fabricated ratings or first-hand outcomes. A partnership never changes the assessment — see how we make money.
Frequently asked
- Does the introductory amount continue after the first purchase?
- The treatment card expressly separates the introductory and ongoing amounts. Use the ongoing figure when comparing continuing care, while retaining the initial payment in a first-year budget. Check the order summary for the next charge and whether an optional additional treatment changes that price. A larger protocol is not interchangeable with the single-medication offer.
- Do the older terms establish an exact four-week billing cycle?
- The approximate twenty-eight-to-thirty-day membership section appears within a separate men’s-health program description. It should not automatically establish the payment cycle of a GLP-1 order. Request the actual renewal dates for the selected offer. Weekly injection instructions describe medication use, not permission to substitute a four-week charge for a published monthly rate.
- Who handles clinical questions after enrollment?
- The current consent places the provider-patient relationship with Keeva and the assigned clinician, while Homera handles platform administration. Obtain the practitioner’s contact route and credentials when matched. Ask how follow-up is scheduled and how records reach another treating professional. A named medical leader on a marketing page does not identify the clinician assigned to you.
- Is an oral alternative available now?
- The homepage marks the needle-free ODT protocol as coming soon. The single-treatment offer describes injections. Do not select an injection plan expecting it to include an oral replacement; ask whether a currently available prescription actually meets your preference and obtain its separate instructions and price before deciding.
- What should I expect about shipping?
- The product advertises free expedited shipping, while the general policy describes processing, longer transit estimates and charges calculated during purchase. Confirm which terms apply to the selected prescription and how to report an error. An estimate is not a guaranteed arrival date, and clinical approval must be considered separately from carrier transit.
- Can I stop care and recover an earlier payment?
- The shipping policy treats prescription sales as final and directs filling-error concerns to support. The older membership language also describes nonrefundable paid fees, but its program scope needs clarification. Obtain the GLP-1 cancellation deadline and any clinical-rejection remedy before paying. Stopping the next renewal and reversing an already fulfilled prescription are different requests.
- Where is Maves available?
- The current About page names thirty-six service states. That is a seller footprint, not independent licensing confirmation or a promise that every listed treatment is available in each location. Check your physical location with the assigned clinician, particularly when traveling, and verify the selected prescription rather than relying on the platform’s general reach.
- What should I know before submitting records?
- The privacy policy distinguishes platform information practices from clinical records and describes sharing for service delivery and other stated purposes. The clinical consent separately addresses health information and electronic communications. Use the appropriate clinical channel, review communication preferences and ask how to obtain a record copy. Keep marketing preferences distinct from messages needed to manage your care.
- Is Maves expensive compared with other GLP-1 providers?
- Maves is listed from $249/mo in this comparison. The 387 reviewed GLP-1 providers with a listed monthly starting amount range from $76 to $1299, with a median of $179. That puts Maves above the median. The comparison excludes 192 other reviewed GLP-1 providers. Medicines, doses and payment commitments differ. Confirm the medication, renewal charge and included visits, supplies and delivery before deciding.